On June 30, 2022, the U.S. Food and Drug Administration (FDA) issued a warning letter to Klarity Kratom, a manufacturer of kratom products, highlighting significant regulatory concerns. The letter criticized the company for making unsubstantiated health claims regarding the benefits of its products, which violated FDA regulations governing dietary supplements. Additionally, the FDA raised alarms about potential safety risks associated with kratom consumption, including addiction and adverse health effects. The letter further noted issues of misbranding, indicating that product labeling failed to comply with federal standards. The FDA required Klarity Kratom to cease misleading marketing practices and take corrective actions to ensure compliance with applicable regulations. This warning underscores the ongoing scrutiny of kratom products in the market and the importance of regulatory adherence for consumer safety.
Menu
